Matthew Venezia
Stock Analyst at Alliance Global Partners
(0.35)
# 4,575
Out of 5,133 analysts
16
Total ratings
18.8%
Success rate
-16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Venezia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterated: Buy | $22 | $8.18 | +168.95% | 1 | Oct 15, 2026 | |
| IMNM Immunome | Initiated Coverage: Buy | $32 | $18.77 | +70.48% | 1 | Sep 21, 2026 | |
| AKTX Akari Therapeutics, | Reiterated: Buy | $20 | $6.80 | +186.76% | 1 | Sep 16, 2026 | |
| MDCX Medicus Pharma | Reiterated: Buy | $50 | $1.95 | +2,464.10% | 1 | Sep 14, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | n/a | $9.53 | - | 8 | Jul 30, 2026 | |
| NTHI NeOnc Technologies Holdings | Initiated Coverage: Buy | $13 | $4.91 | +164.77% | 1 | May 19, 2026 | |
| PLUR Pluri | Initiated Coverage: Buy | $12 | $1.05 | n/a | 1 | Jun 2, 2025 | |
| CBUS Cibus | Reiterated: Buy | $24 | $1.13 | n/a | 2 | May 9, 2025 |
Verastem
Oct 15, 2026
Reiterated: Buy
Price Target: $22
Current: $8.18
Upside: +168.95%
Immunome
Sep 21, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $18.77
Upside: +70.48%
Akari Therapeutics,
Sep 16, 2026
Reiterated: Buy
Price Target: $20
Current: $6.80
Upside: +186.76%
Medicus Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $50
Current: $1.95
Upside: +2,464.10%
Capricor Therapeutics
Jul 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.53
Upside: -
NeOnc Technologies Holdings
May 19, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $4.91
Upside: +164.77%
Pluri
Jun 2, 2025
Initiated Coverage: Buy
Price Target: $12
Current: $1.05
Upside: n/a
Cibus
May 9, 2025
Reiterated: Buy
Price Target: $24
Current: $1.13
Upside: n/a